The mechanism of action of trastuzumab involves binding to the extracellular domain of the HER2 receptor. This binding inhibits the proliferation of tumor cells that overexpress HER2 and can also mediate antibody-dependent cellular cytotoxicity (ADCC). The drug is particularly effective in HER2-positive breast cancer, which tends to be more aggressive than HER2-negative types.
